FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185691303> ?p ?o ?g. }

• W3185691303 endingPage "1056" @default.
• W3185691303 startingPage "1056" @default.
• W3185691303 abstract "<h3>Importance</h3> Biologics and targeted therapies, such as apremilast, are efficient treatments to manage moderate to severe psoriasis. More information about the risk of serious infection is needed for the newest treatment options in a real-world setting. <h3>Objective</h3> To assess the risk of serious infection among biologics and apremilast used to treat psoriasis, with etanercept as the comparator. <h3>Design, Setting, and Participants</h3> This nationwide cohort study from France involved data from the National Health Data System covering approximately 99% of the French population. All adults with psoriasis, defined as receiving at least 2 prescriptions of a topical vitamin D derivative within a 2-year period, registered in the database between January 1, 2008, and May 31, 2019, were eligible. The study population included those who were new users of biologic agents or apremilast (ie, without any prescriptions of a biologic or apremilast during the previous year). Patients with HIV infection or a history of cancer, transplant, or serious infection were excluded. End of follow-up was January 31, 2020. <h3>Main Outcome Measures</h3> The primary end point was a serious infection in a time-to-event analysis using propensity score–weighted Cox proportional hazards regression models, estimating weighted hazard ratios (wHRs) and 95% CIs. <h3>Results</h3> A total of 44 239 new users of biologic treatment were identified (mean [SD] age, 48.4 [13.8] years; 22 866 [51.7%] men; median follow-up, 12 months [interquartile range, 7-24 months]). A total of 29 618 (66.9%) were prescribed a tumor necrosis factor inhibitor first, 6658 (15.0%) an interleukin (IL) 12/23 inhibitor, 4093 (9.3%) an IL-17 inhibitor, 526 (1.2%) an IL-23 inhibitor, and 3344 (7.6%) apremilast. The total number of serious infections was 1656, and the overall crude incidence rate was 25.0 (95% CI, 23.8-26.2) per 1000 person-years. The most frequent serious infections were gastrointestinal infections (645 patients [38.9%]). After adjusting for time-dependent covariables, risk of serious infections was higher for new users of adalimumab (wHR, 1.22; 95% CI, 1.07-1.38) or infliximab (wHR, 1.79; 95% CI 1.49-2.16) vs etanercept, whereas ustekinumab was associated with a lower risk of having a serious infection (wHR, 0.79; 95% CI, 0.67-0.94). Risk of serious infections was not increased for new users of IL-17 and the IL-23 inhibitor guselkumab or apremilast vs etanercept. Risk of serious infections was increased with concomitant nonsteroidal anti-inflammatory drugs or systemic corticosteroids. <h3>Conclusions and Relevance</h3> In this cohort study of individuals with moderate to severe psoriasis, risk of serious infections was increased in new users of infliximab and adalimumab vs etanercept, whereas ustekinumab users had lower risk of having a serious infection but not new users of IL-17 and IL-23 inhibitors or apremilast. Other observational studies are needed to confirm results for the most recent drugs." @default.
• W3185691303 created "2021-08-02" @default.
• W3185691303 creator A5005558695 @default.
• W3185691303 creator A5046017646 @default.
• W3185691303 creator A5057668291 @default.
• W3185691303 creator A5059005646 @default.
• W3185691303 creator A5079683534 @default.
• W3185691303 creator A5080099253 @default.
• W3185691303 date "2021-09-01" @default.
• W3185691303 modified "2023-10-14" @default.
• W3185691303 title "Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis" @default.
• W3185691303 cites W1521666696 @default.
• W3185691303 cites W1692288477 @default.
• W3185691303 cites W2056108924 @default.
• W3185691303 cites W2097170399 @default.
• W3185691303 cites W2097896724 @default.
• W3185691303 cites W2135210871 @default.
• W3185691303 cites W2207240463 @default.
• W3185691303 cites W2275737843 @default.
• W3185691303 cites W2341137663 @default.
• W3185691303 cites W2378098209 @default.
• W3185691303 cites W2521108778 @default.
• W3185691303 cites W2741789802 @default.
• W3185691303 cites W2744472213 @default.
• W3185691303 cites W2754072312 @default.
• W3185691303 cites W2767910653 @default.
• W3185691303 cites W2785674074 @default.
• W3185691303 cites W2794670498 @default.
• W3185691303 cites W2797152839 @default.
• W3185691303 cites W2888659553 @default.
• W3185691303 cites W2904014975 @default.
• W3185691303 cites W2944612481 @default.
• W3185691303 cites W2983002682 @default.
• W3185691303 cites W3160623885 @default.
• W3185691303 cites W4206739528 @default.
• W3185691303 cites W4230628521 @default.
• W3185691303 cites W4231142916 @default.
• W3185691303 cites W4240744549 @default.
• W3185691303 cites W4240944551 @default.
• W3185691303 cites W4242775467 @default.
• W3185691303 cites W4245660495 @default.
• W3185691303 cites W4245864220 @default.
• W3185691303 cites W4248756033 @default.
• W3185691303 cites W4248957420 @default.
• W3185691303 cites W4297900878 @default.
• W3185691303 doi "https://doi.org/10.1001/jamadermatol.2021.2599" @default.
• W3185691303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8295892" @default.
• W3185691303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34287624" @default.
• W3185691303 hasPublicationYear "2021" @default.
• W3185691303 type Work @default.
• W3185691303 sameAs 3185691303 @default.
• W3185691303 citedByCount "30" @default.
• W3185691303 countsByYear W31856913032021 @default.
• W3185691303 countsByYear W31856913032022 @default.
• W3185691303 countsByYear W31856913032023 @default.
• W3185691303 crossrefType "journal-article" @default.
• W3185691303 hasAuthorship W3185691303A5005558695 @default.
• W3185691303 hasAuthorship W3185691303A5046017646 @default.
• W3185691303 hasAuthorship W3185691303A5057668291 @default.
• W3185691303 hasAuthorship W3185691303A5059005646 @default.
• W3185691303 hasAuthorship W3185691303A5079683534 @default.
• W3185691303 hasAuthorship W3185691303A5080099253 @default.
• W3185691303 hasBestOaLocation W31856913031 @default.
• W3185691303 hasConcept C119060515 @default.
• W3185691303 hasConcept C126322002 @default.
• W3185691303 hasConcept C16005928 @default.
• W3185691303 hasConcept C187212893 @default.
• W3185691303 hasConcept C207103383 @default.
• W3185691303 hasConcept C2776260265 @default.
• W3185691303 hasConcept C2777226972 @default.
• W3185691303 hasConcept C2777575956 @default.
• W3185691303 hasConcept C2778975655 @default.
• W3185691303 hasConcept C2779134260 @default.
• W3185691303 hasConcept C2780132546 @default.
• W3185691303 hasConcept C2780564577 @default.
• W3185691303 hasConcept C2781427535 @default.
• W3185691303 hasConcept C2908647359 @default.
• W3185691303 hasConcept C44249647 @default.
• W3185691303 hasConcept C71924100 @default.
• W3185691303 hasConcept C99454951 @default.
• W3185691303 hasConceptScore W3185691303C119060515 @default.
• W3185691303 hasConceptScore W3185691303C126322002 @default.
• W3185691303 hasConceptScore W3185691303C16005928 @default.
• W3185691303 hasConceptScore W3185691303C187212893 @default.
• W3185691303 hasConceptScore W3185691303C207103383 @default.
• W3185691303 hasConceptScore W3185691303C2776260265 @default.
• W3185691303 hasConceptScore W3185691303C2777226972 @default.
• W3185691303 hasConceptScore W3185691303C2777575956 @default.
• W3185691303 hasConceptScore W3185691303C2778975655 @default.
• W3185691303 hasConceptScore W3185691303C2779134260 @default.
• W3185691303 hasConceptScore W3185691303C2780132546 @default.
• W3185691303 hasConceptScore W3185691303C2780564577 @default.
• W3185691303 hasConceptScore W3185691303C2781427535 @default.
• W3185691303 hasConceptScore W3185691303C2908647359 @default.
• W3185691303 hasConceptScore W3185691303C44249647 @default.
• W3185691303 hasConceptScore W3185691303C71924100 @default.
• W3185691303 hasConceptScore W3185691303C99454951 @default.
• W3185691303 hasIssue "9" @default.

• next